NYLIM
ADMA icon

New York Life Investment Management’s ADMA Biologics ADMA Stock Holding History

New York Life Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,859
Closed -$362K – 858
2024
Q1 		$362K Buy
+54,859
New +$300K ﹤0.01% 1180

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

New York Life Investment Management's ADMA Position: Q2 2024 in Review

New York Life Investment Management sold out of ADMA Biologics (ADMA) in Q2 2024, closing a stake of 54,859 shares — an estimated $362K sold.

New York Life Investment Management first reported a position in ADMA in Q1 2024 and held it in 1 quarter. The position peaked at $362K in Q1 2024. 252 funds tracked by Wall St. Rank hold ADMA as of Q2 2024.

  • New York Life Investment Management reported no remaining ADMA Biologics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 54,859 ADMA Biologics shares in Q2 2024, an estimated $362K.
  • New York Life Investment Management first reported a position in ADMA Biologics in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's ADMA Biologics position peaked at $362K in Q1 2024.
  • 252 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.